Table 3.
Regression of murine B16 melanoma in SCID mice engrafted with murine splenocyte subpopulations and treated with BAT
| Splenocyte engraftment | No. of metastases per BAT treatment
|
|
|---|---|---|
| − | + | |
| Nonengrafted | >250 | >250 |
| Nondepleted | 217 ± 65 | 7 ± 3 |
| CD3 depleted | >250 | >250 |
| NK depleted | >250 | 84 ± 38 |
SCID mice were engrafted i.p. with splenocytes (5 × 107/mouse) from C57BL mice or from C57BL mice that were injected with anti-CD3 (100 μg/mouse) or anti-asialoGM1 (100 μg/mouse) 1 day prior to isolation of splenocytes for engraftment. B16 melanoma cells were injected i.v. 5 days later. BAT (10 μg/mouse) was injected i.v. 10 days following tumor administration. Mice were sacrificed 24 days posttumor inoculation and the number of lung metastases was determined. Five SCID mice were used in each group and the results are expressed as the mean ± SD.